End of coverage

From 2nd January 2024, we will no longer include in our research universe:HMSBaslerTKH GroupInfineonSTMicroelectronics

Model update

We have updated our estimates ahead of Q3 2023 results. Our estimates change by low-single digits, as detailed in the table below. PT and Buy recommendation unchanged.

Bryan, Garnier & Co Technology Daily | CPGI, SOW, COP, ALVGV, SEMIS

Avantium: factoring in the reverse stock split

Yesterday, following unanimous approval of a 1:10 reverse stock split by the Board on 14th May, Avantium began trading on a post-reverse stock split basis. As a result of the reverse stock split, shareholders have been allotted one new ordinary share with a par value of EUR1.00 for every 10 existin

ONWARD: Expanding BCI clinical evidence with 5th implant milestone

This morning, ONWARD announced two additional successful implants of its ARC-BCI system in SCI patients, bringing the total to five as part of ongoing clinical feasibility studies. The latest cases involved a 48-year-old man (upper-limb SCI, injury in 2024) and a 37-year-old woman (lower-limb SCI,

Cinclus Pharma: start of phase 3 reiterated for Q3'25

Cinclus Pharma reported its Q1 results which focused on balance sheet items and a recap of corporate achievements for the quarter, with a cash position at SEK523.9m and an EBIT at SEK(47.519m). With the current cash position and operational cash burn, we forecast a runway into H1 2027. On the opera